公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial | Soo, Ross A; Huat Tan, Eng; Hayashi, Hidetoshi; Seto, Takashi; CHIA-CHI LIN ; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Liu, Geoffrey; Abbattista, Antonello; Martini, Jean-François; Hooi Wong, Chew; Toffalorio, Francesca; Solomon, Benjamin J | Lung cancer (Amsterdam, Netherlands) | 9 | | |
2018 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012 | Mehra R.; Seiwert T.Y.; Gupta S.; Weiss J.; Gluck I.; Eder J.P.; Burtness B.; Tahara M.; Keam B.; Kang H.; Muro K.; Geva R.; Chung H.C.; CHIA-CHI LIN ; Aurora-Garg D.; Ray A.; Pathiraja K.; Cheng J.; Chow L.Q.M.; Haddad R. | British Journal of Cancer | 303 | 256 | |
2023 | Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study | Oh, Do-Youn; Algazi, Alain; Capdevila, Jaume; Longo, Federico; Miller, Wilson; Chun Bing, Jerry Tan; Bonilla, Carlos Eduardo; Chung, Hyun Cheol; Guren, Tormod K; CHIA-CHI LIN ; Motola-Kuba, Daniel; Shah, Manisha; Hadoux, Julien; Yao, Lili; Jin, Fan; Norwood, Kevin; Lebellec, Loïc | Cancer | 5 | 3 | |
2013 | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | HSIANG-FONG KAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Future Oncology | 7 | 6 | |
2021 | Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasm | Chang, Ling-Kai; Chen, Kuan-Chih; MEI-FANG CHENG ; CHIA-CHI LIN ; HSIU-PO WANG ; Sung, Chia-Tung; Chen, Jou-Ho; RUOH-FANG YEN ; CHIA-LIN HSU ; SHYANG-RONG SHIH | Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society | 2 | 2 | |
2020 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials | Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; CHIA-CHI LIN ; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. | The Lancet Oncology | 308 | 250 | |
2006 | Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells | YEONG-SHIAU PU ; Hsieh M.-W.; Wang C.-W.; Liu G.-Y.; CHAO-YUAN HUANG ; CHIA-CHI LIN ; Guan J.-Y.; Lin S.-R.; Hour T.-C. | Biochemical Pharmacology | 38 | 35 | |
2015 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis | BIN-CHI LIAO ; JIH-HSIANG LEE ; CHIA-CHI LIN ; YA-FANG CHEN ; Chang C.-H.; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 137 | 113 | |
2009 | Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer | CHIA-CHI LIN ; CHIH-HSIN YANG | Targeted Oncology | 11 | 9 | |
2021 | Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan | Yin O.; Iwata H.; CHIA-CHI LIN ; Tamura K.; Watanabe J.; Wada R.; Kastrissios H.; AbuTarif M.; Garimella T.; Lee C.; Zhang L.; Shahidi J.; LaCreta F. | Clinical Pharmacology and Therapeutics | 21 | 15 | |
2021 | Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' Orbitopathy | SHYANG-RONG SHIH ; SHU-LANG LIAO ; Shih, Chih-Wei; YI-HSUAN WEI ; Lu, Ting-Xuan; Chou, Chien-Hsiang; Yen, Er-Yen; YI-CHENG CHANG ; CHIA-CHI LIN ; Chi, Yu-Chiao; WEI-SHIUNG YANG ; FENG-CHIAO TSAI | Ocular immunology and inflammation | 4 | 4 | |
2020 | A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors | Naing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; CHIA-CHI LIN ; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M. | Journal for ImmunoTherapy of Cancer | 55 | 46 | |
2022 | First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma | Italiano A.; Cassier P.A.; CHIA-CHI LIN ; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. | Cancer Immunology, Immunotherapy | 5 | 5 | |
2022 | A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors | Chan, Stephen L; Schuler, Martin; Kang, Yoon-Koo; Yen, Chia-Jui; Edeline, Julien; Choo, Su Pin; CHIA-CHI LIN ; Okusaka, Takuji; Weiss, Karl-Heinz; Macarulla, Teresa; Cattan, Stéphane; Blanc, Jean-Frederic; Lee, Kyung-Hun; Maur, Michela; Pant, Shubham; Kudo, Masatoshi; Assenat, Eric; Zhu, Andrew X; Yau, Thomas; Lim, Ho Yeong; Bruix, Jordi; Geier, Andreas; Guillén-Ponce, Carmen; Fasolo, Angelica; Finn, Richard S; Fan, Jia; Vogel, Arndt; Qin, Shukui; Riester, Markus; Katsanou, Vasiliki; Chaudhari, Monica; Kakizume, Tomoyuki; Gu, Yi; Porta, Diana Graus; Myers, Andrea; Delord, Jean-Pierre | Journal of experimental & clinical cancer research : CR | 20 | | |
2013 | First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 15 | 16 | |
2014 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial | CHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K. | European Journal of Cancer | 41 | 40 | |
2016 | Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study | CHIH-HSIN YANG ; Srimuninnimit V; Ahn M.-J; CHIA-CHI LIN ; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. | Journal of Thoracic Oncology | 22 | 20 | |
2010 | Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. | YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Discovery medicine | 13 | 12 | |
2007 | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; Keng H.-Y.; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Anti-Cancer Drugs | 32 | 29 | |
2008 | Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial | CHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 14 | 11 | |